PMID- 32503415
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20231213
IS  - 1129-2377 (Electronic)
IS  - 1129-2369 (Print)
IS  - 1129-2369 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 5
TI  - Short-term efficacy and safety of lasmiditan, a novel 5-HT(1F) receptor agonist, 
      for the acute treatment of migraine: a systematic review and meta-analysis.
PG  - 66
LID - 10.1186/s10194-020-01138-x [doi]
LID - 66
AB  - BACKGROUND: Migraine has been recognized as one of common diseases in the world 
      whose current treatment options are not ideal. Lasmiditan, an oral 
      5-hydroxytryptamine (HT)(1F) receptor agonist, appears more promising for the 
      acute treatment of migraine because of considerably better effect profiles with 
      no severe adverse events (AEs). This review aimed to systematically evaluate the 
      efficacy and safety of lasmiditan from the results of randomized controlled 
      trials (RCTs). METHODS: PubMed, Cochrane Library, Embase were searched on 
      lasmiditan for the acute treatment of migraine from inception of the databases to 
      Feb 1, 2020. Pain free and pain relief, global impression (very much/much 
      better), and no/mild disability at 2 h in efficacy; total treatment-emergent 
      adverse events (TEAEs), dizziness, nausea, fatigue, paraesthesia and somnolence 
      in safety were extracted from the included studies. A systematic review and 
      meta-analysis was performed using Review Manager Software version 5.3 (RevMan 
      5.3). RESULTS: Four RCTs with a total of 4960 subjects met our inclusion 
      criteria. The overall effect estimate showed that lasmiditan was significantly 
      superior to placebo in terms of pain free (RR 1.71, 95% CI 1.55-1.87), pain 
      relief (RR 1.40, 95% CI 1.33-1.47), global impression (very much/much better) (RR 
      1.55, 95% CI 1.44-1.67), and no/mild disability (RR 1.15, 95% CI 1.10-1.20) at 
      2 h. For the safety, significant number of patients experienced TEAEs with 
      lasmiditan than with placebo (RR 2.77, 95% CI 2.53-3.03), most TEAEs were central 
      nervous system (CNS)-related and included dizziness (RR 5.81, 95% CI 4.72-7.14), 
      nausea (RR 2.58, 95% CI 1.87-3.57), fatigue (RR 5.38, 95% CI 3.78-7.66), 
      paraesthesia (RR 4.48, 95% CI 3.33-6.02), and somnolence (RR 2.82, 95% CI 
      2.18-3.66). CONCLUSIONS: This meta-analysis suggests that lasmiditan is effective 
      for the acute treatment of migraine with a higher incidence of CNS-related 
      adverse reactions compared with placebo. Long-term, open-label, multi-dose trials 
      are required to verify the current findings.
FAU - Hou, Min
AU  - Hou M
AD  - Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, 
      400042, P. R. China.
FAU - Xing, Haiyan
AU  - Xing H
AD  - Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, 
      400042, P. R. China.
FAU - Li, Chen
AU  - Li C
AD  - Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, 
      400042, P. R. China.
FAU - Wang, Xianfeng
AU  - Wang X
AD  - Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, 
      400042, P. R. China.
FAU - Deng, Dongmei
AU  - Deng D
AD  - Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, 
      400042, P. R. China.
FAU - Li, Juan
AU  - Li J
AD  - Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, 
      400042, P. R. China.
FAU - Zhang, Pan
AU  - Zhang P
AD  - Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, 
      400042, P. R. China.
FAU - Chen, Jianhong
AU  - Chen J
AD  - Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, 
      400042, P. R. China. yaojike2017@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200605
PL  - England
TA  - J Headache Pain
JT  - The journal of headache and pain
JID - 100940562
RN  - 0 (Benzamides)
RN  - 0 (Piperidines)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 760I9WM792 (lasmiditan)
SB  - IM
MH  - Benzamides/adverse effects/*therapeutic use
MH  - Dizziness/chemically induced
MH  - Humans
MH  - Migraine Disorders/*diagnosis/*drug therapy
MH  - Nausea/chemically induced
MH  - Piperidines/adverse effects/*therapeutic use
MH  - Pyridines/adverse effects/*therapeutic use
MH  - Receptors, Serotonin/*physiology
MH  - Serotonin Receptor Agonists/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vertigo/chemically induced
MH  - Receptor, Serotonin, 5-HT1F
PMC - PMC7275414
OTO - NOTNLM
OT  - 5-HT1F receptor agonist
OT  - Lasmiditan
OT  - Meta-analysis
OT  - Migraine
COIS- The authors declare that they have no competing interests.
EDAT- 2020/06/07 06:00
MHDA- 2020/09/25 06:00
PMCR- 2020/06/05
CRDT- 2020/06/07 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/06/05 00:00 [pmc-release]
AID - 10.1186/s10194-020-01138-x [pii]
AID - 1138 [pii]
AID - 10.1186/s10194-020-01138-x [doi]
PST - epublish
SO  - J Headache Pain. 2020 Jun 5;21(1):66. doi: 10.1186/s10194-020-01138-x.